In the immune system, many tolerance checkpoints exist to prevent self-antigens from stimulating the relentless growth of self-reactive B and T lymphocytes. The genes and molecular pathways underpinning these checkpoints overlap with those involved in tumor suppression. As with an inherited predisposition to cancer, inherited defects in self-tolerance genes typically precipitate autoimmune disease stochastically after a latent phase. Multiple mutations, inherited and somatic, may be needed before a self-reactive clone bypasses sequential tolerance checkpoints resulting in the emergence of autoimmune disease.
Introduction
Why does autoimmunity develop in about 5% of people? Autoimmune diseases arise when the immune system turns its antimicrobial defenses upon normal components of the body such as insulin-producing pancreatic cells in Type 1 diabetes or chromatin in systemic lupus erythematosus. Immunologists have identified a number of specific genes and cellular mechanisms involved in immunological self-tolerance that, when disrupted by inherited mutations, cause autoimmune disease. Despite complete failure of individual tolerance mechanisms, these autoimmune diseases have a delayed stochastic penetrance that resembles the onset of cancer resulting from inherited mutations in tumor suppressor proteins such as p53. Such tumors have delayed stochastic penetrance because other regulatory layers prevent aberrant cells from accumulating and are only bypassed after multiple somatic mutations accumulate in a single clone. Multiple control systems also prevent accumulation of autoimmune lymphocytes, and these control systems depend on genes known to suppress lymphoid cancers such as B cell lymphoma and myeloma. This Review analyzes the parallels and overlaps in the evolution of rogue lymphocyte clones in autoimmune diseases and lymphoid cancer, drawing together concepts from the latter that inform our understanding of autoimmunity.
Relentless Stimulation of Lymphocyte Growth
Physiological mechanisms of V(D)J recombination, gene conversion, and somatic mutation equip the T and B lymphocytes of our immune system with different receptors for detecting antigen. T lymphocytes express T cell receptors (TCRs), and B cells express B lymphocyte receptors (BCRs), which are membrane-spanning immunoglobulin isoforms. When engaged by antigen, these receptors can switch on powerful cell growth and survival pathways. For example, the transcription factor nuclear factor kappa B (NF-κB) activates a range of growth and survival factors; phosphatidylinositol-3-kinase (PI3K) activates the protein kinase AKT; Ras activates ERK; MYC activates many cellular growth genes; and the BCL-2, BCL-XL, and A1(Bfl1) proteins suppress apoptosis. Activation of these pathways by antigen triggers clonal lymphocyte proliferation, mobilizing immunity against infection (Figure 1 ).
Lymphoid cancers arise from uncontrolled activity of these cell growth and survival pathways. Constitutively active aberrant antigen receptors promote lymphoid cancer: for example, truncated BCRs (Corcos et al., 2001) in lymphoma and myeloma, or uncontrolled activity of the preTCR in T cell acute lymphoblastic leukemia (Winandy et al., 1999) . Viral gene products act downstream to mimic constitutively active antigen receptors, illustrated by leukemogenic retroviruses expressing mutated versions of MYC and NF-κB c-REL (Grumont et al., 2002) and by the Epstein-Barr virus transforming protein LMP2A (Casola et al., 2004) . Chromosomal translocations that constitutively activate MYC, BCL-2, or upstream activators of NF-κB (BCL-10, MALT-1) are found in many human lymphomas.
Relentless stimulation of antigen receptors and lymphocyte growth can also arise upstream of antigen receptors. Chronic infection provides a constantly replenished supply of antigen to stimulate lymphocytes; for example, infections with the bacterium Helicobacter pylori, hepatitis C virus, or human immunodeficiency virus predispose individuals to lymphoid cancer (Suarez et al., 2006) . Dietary antigens also stimulate antigen receptors relentlessly, and chronic T lymphocyte responses to wheat gluten can progress from intestinal inflammation to intestinal lymphoma (Cellier et al., 2000) .
The diverse array of self-antigens poses the greatest potential source for relentless lymphocyte stimulation. More than half of all antigen receptors randomly gen-
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Christopher C. Goodnow 1, * erated by V(D)J recombination recognize self-antigens (Ignatowicz et al., 1996; Wardemann et al., 2003; Zerrahn et al., 1997) . Given that millions of new lymphocytes are produced daily, there is a massive flow of lymphocytes into the system with the potential for endless growth stimulation by self-antigen.
Keeping Autoimmune Lymphocyte Growth in Check
Growth of autoimmune lymphocytes induced by selfantigens is blocked by mechanisms that either override or limit antigen receptor signaling to NF-κB, PI3K/AKT, MYC, and BCL-2/BCL-XL/A1 (Figure 1 ). These mechanisms act as distinct checkpoints placed along the lymphocyte differentiation and activation sequence ( Figure  2 ). The different checkpoints are reviewed systematically elsewhere , and we will focus here on several better understood checkpoints that illustrate key concepts. Negative selection of thymocytes illustrates an efficient override mechanism. When V(D)J recombination in immature thymic T cells yields a TCR binding strongly to self-antigen, the TCR signals transcription and synthesis of BIM, a proapoptotic BH3-only protein that inhibits the antiapoptotic proteins BCL-2 and BCL-XL (Liston et al., 2004; Strasser, 2005) . BIM-induced apoptosis eliminates strongly self-reactive thymocytes, and inherited BIM deficiency in mice cripples this process and predisposes them to autoimmunity and to lymphoid cancer (Egle et al., 2004b; Strasser, 2005) . The FAS/CD95 receptor provides a complementary mechanism to override growth stimulation by self-antigens in peripheral T and B cells (Krammer, 1999; Nagata and Golstein, 1995) . FAS ligand is induced by antigen on T cells and triggers apoptosis of self-reactive T and B cells through FAS signaling to caspases 8 and 10. Like BIM, FAS also exemplifies the molecular overlap between self-tolerance and tumor suppression because both autoimmune disease and lymphoma arise in humans and mice with inherited FAS mutations (Nagata and Golstein, 1995; Rieux-Laucat et al., 1995; Straus et al., 2001) . Moreover, somatic FAS mutations have been documented in autoimmune disease (Holzelova et al., 2004) and in lymphoma (Gronbaek et al., 1998 ).
An overlapping set of growth-limiting mechanisms also counters the potential for self-antigen to stimulate relentless activation of NF-κB, PI3K/AKT, c-MYC, and BCL-2/BCL-XL/A1 pathways. Growth of T cells requires costimulation by a second signal (Lafferty et al., 1983) delivered through the CD28 receptor (Greenwald et al., 2005; Kane et al., 2002) . In naive T cells, TCR engagement alone activates PI3K and NF-κB pathways inefficiently, so that high amounts of antigen are needed to induce production of the autocrine T cell growth factor interleukin (IL)-2. Insufficient induction renders the cell refractory to TCR stimulated growth-a phenomenon termed anergy. When TCR engagement alone is sufficient to initiate proliferation, it is overridden by apoptosis because of insufficient induction of the NF-κB target, BCL-XL (Boise et al., 1995) . These outcomes predominate in peripheral T cells that recognize self-antigens as they are usually stimulated by their TCR alone. When antigen-presenting cells capture and present microbial antigens, however, they transiently express B7.1 and B7.2, which are ligands that activate CD28 and dramatically enhance TCR activation of PI3K/AKT and NF-κB (Kane et al., 2002; Narayan et al., 2006) . CD28 costimulation thus selectively relieves a critical growth limitation in T cells that recognize microbial antigens. T cell dependence on CD28, and susceptibility to FASinduced apoptosis, is abolished when the PI3K pathway Multiple control mechanisms limit or override the potential for antigen receptors to stimulate relentless growth of lymphocytes. Binding of antigen to antigen receptors can activate potent growth and survival signaling pathways (black arrows). In lymphocytes recognizing microbial antigens, these signals drive clonal expansion of antimicrobial lymphocytes. Once the microbe is eliminated this removes the source of antigen and induction of clonal growth. Self-antigens cannot be cleared in this way, posing the potential for chronic receptor activation and endless growth induction in self-reactive clones. Mutations that cripple mechanisms for countering this potential lead to outgrowth of autoimmune disease clones and to lymphoid malignancy.
is overactive due to an inherited deficiency of the PI3-phosphatase, PTEN (Buckler et al., 2006; Di Cristofano et al., 1999; Jones et al., 2002; Marsh et al., 1999; Suzuki et al., 2001) , representing another example of a control gene that, when mutated, results in a predisposition to both autoimmunity and cancer.
Chronic stimulation of the TCR induces feedback mechanisms that further limit the potential for relentless growth stimulation. One of these is CTLA4, a second receptor for B7.1 and B7.2 that opposes TCR-CD28-induced proliferation by competing with CD28 for its B7 ligands and by recruiting inhibitory tyrosine phosphatases that dampen TCR signaling (Greenwald et al., 2005) . CTLA4-deficient mice develop a massive accumulation of activated polyclonal T cells, and CTLA-4 abnormalities are associated with autoimmune susceptibility in humans (Ueda et al., 2003) . Other inhibitory receptors induced by chronic TCR stimulation are CD5 (Smith et al., 2001; Wong et al., 2001 ) and PD-1 (Greenwald et al., 2005) . Within the T cell, chronic TCR stimulation induces the inhibitory ubiquitin ligase CBL-B (Heissmeyer et al., 2004) and, under particular conditions, the transcription factor FOXP3. FOXP3 induces CTLA4 and represses the tyrosine kinases ZAP-70 and ITK, IL-2, and the receptor for IL-7, a critical T cell survival factor provided by the lymphoid stroma (Wan and Flavell, 2007; Wu et al., 2006; Zheng et al., 2007) . In self-reactive T cells expressing FOXP3, despite constant TCR stimulation by self-antigens, cell growth and survival depends upon IL-2 provided by other T cells rather than autocrine IL-2 or IL-7 from the stroma Williams and Rudensky, 2007) .
BCR engagement by antigen also has limited capacity to activate NF-κB, PI3K/AKT, MYC, and BCL-2/BCL-XL/ A1 growth pathways in B cells. Binding of chronic antigen alone is usually insufficient to promote cell division, and instead induces inhibitory feedback mechanisms that make the cell anergic. Anergy in B cells involves selective uncoupling of the BCR from NF-κB signaling to MYC, BCL-XL, and A1 (Glynne et al., 2000) , whereas BCR signaling that results in growth-override mechanisms such as BIM-induced apoptosis remains intact (Strasser, 2005) . The limits on BCR signaling for NF-κB activation and B cell growth are relieved when the BCR captures a microbial antigen. Simultaneous engagement of Toll-like receptors (TLRs) by microbial componentssuch as the lipopolysaccharide cell walls of bacteria or double-stranded RNAs of virions-acts synergistically with BCR stimulation to activate NF-κB, resulting in B cell proliferation (Beutler, 2004; Marshak-Rothstein, 2006) . Microbial antigens are also tagged with the complement cleavage product C3d. When BCRs bind to C3d-tagged antigen, C3d simultaneously engages its CD21 receptor and, through preformed CD21/CD19 clusters, promotes BCR-induced phosphorylation of CD19, which is a major docking site for activation of PI3 kinase. This provides a second way to dramatically enhance proliferation of microbe-reactive, but not self-reactive, B cells (Fearon and Carroll, 2000) .
Lymphocyte cooperation provides a major mechanism for relieving growth-limiting checkpoints in cells responding to microbial antigens. Receptors for CD40 ligand and IL-4 on B cells activate the NF-κB and PI3K/ AKT pathways, respectively, and act synergistically with BCR signaling to promote B cell growth and survival (Foy et al., 1996; Kovanen and Leonard, 2004 ). CD40L and IL-4 are produced focally by CD4+ helper T lymphocytes that have themselves been successfully stimulated to grow. As many checkpoints override or limit selfreactive T cell production of CD40L and IL-4, these are primarily made by T cells that recognize microbial antigens. Hence the potential for B cell growth in response to self-antigen is limited by dependence on two cooperating cells (Bretscher and Cohn, 1970 )-a B cell and a T cell-both of which must bypass multiple checkpoint mechanisms (Figures 2 and 3B) . The probability of a two-cell failure is the square root of either one alone and hence constitutes a powerful checkpoint against autoantibody production.
Multiple Steps Cooperate in Autoimmunity
Autoimmune disease only develops after a considerable latent period in humans and experimental animals that inherit mutations completely disrupting individual tolerance checkpoints. For example, mutations in the transcription factor AIRE cripple thymic negative selection of organ-specific T cells (Liston et al., 2003) . A range of self-antigens that are made only in a particular organ, such as proinsulin expression in the pancreas, is also produced by specialized epithelial cells within the thymus medulla. This specialized thymic display of the body's repertoire of self-antigens depends in part upon Random somatic diversification of antigen receptor genes yields many clones bearing self-reactive receptors. (A) Normally, the survival and growth of these clones is opposed by multiple checkpoints. (B) When an inherited mutation (or a combination of more subtle alleles) disrupts one checkpoint, other checkpoints still oppose survival and growth of most self-reactive clones. Rare clones eventually bypass these additional checkpoints on a stochastic basis. Cooperation between clones-for example between B and T cells recognizing the same self-antigen-provides one bypass mechanism. When the frequency of self-reactive cells increases because of an inherited or somatic disruption of one checkpoint, the probability of forming cooperative pairs increases, explaining the stochastic onset of autoimmunity. (C) As opposed to an inherited defect, chance somatic mutations in a self-reactive clone may disrupt different growth-limit and override mechanisms so that self-antigen stimulates clonal growth, leading to stochastic onset of autoimmunity. (D) Somatic mutations in separate self-reactive clones may lead to cooperating groups of self-reactive clones that help each other to bypass unmutated checkpoints. Combinations of (B), (C), and (D) are also likely-for example inheritance of a heterozygous mutation that is rendered homozygous in rare clones by a somatic mutation.
AIRE and is extinguished when the AIRE gene is defective (Anderson et al., 2002) . AIRE deficiency in humans nevertheless remains clinically latent for many years, with autoimmune polyendocrinopathy developing in an apparently stochastic, stepwise manner (Betterle et al., 1998) . Initially a single organ, often parathyroid or adrenal glands, is compromised in the first decade of life followed after several years by a second or third organ. A similar situation exists in Aire-deficient mice, where few organs and antigens become targets of autoimmunity and only after a latent period, with both parameters changing depending on the mouse strain background and major histocompatibility complex (MHC) genotype (Jiang et al., 2005) . Type 1 diabetes does not occur even in Aire-deficient B6 mice with a diabetes-prone MHC, despite failure of thymic negative selection to major islet-specific antigens. Severe exocrine pancreatitis nevertheless develops with a short latent period when the Aire-mutation is bred to the NOD strain harboring defects in many tolerance checkpoints, suggesting that autoimmune clones that escape thymic deletion must bypass several independent checkpoints before autoimmunity develops.
Key factors affecting the latent period are most defined in lpr mice with homozygous inactivating mutations in Fas (CD95, Tnfrsf6) because this is the longest studied autoimmune-inducing mutation (Cohen and Eisenberg, 1991; Nagata and Golstein, 1995) . In inbred C57BL/6 or C3H mice, Fas mutation causes mild autoantibody secretion against DNA-and RNA-associated antigens and accumulation of B and T cells in lymph nodes starting after three months of age. Autoantibodies appear earlier and reach higher titers when the mutation is combined with an inherently autoimmune-prone strain background, MRL. The event(s) that trigger progression from latent to measurable autoimmunity in Fas-deficient mice do not involve an external trigger such as infection because autoimmunity occurs equally in germ-free animals (Maldonado et al., 1999) .
Expanded B cell clones appear during progression to autoimmunity in Fas-deficient mice, bearing BCRs containing V-elements and somatic V-region mutations that confer high affinity for DNA-and RNA-associated antigens (Shlomchik et al., 1990) . When V(D)J-recombination is distorted to produce particular BCRs by breeding BCR transgenes into Fas-deficient mice, transgenes that increase bone marrow formation of self-reactive B cells against DNA or RNA antigens shorten the latent period and increase autoantibody titers (Chen et al., 2006; Santulli-Marotto et al., 2001) . By contrast, the latent period is prolonged by transgenes that increase self-reactive B cells against a nonchromatin self-antigen but decrease DNA-reactive B cells (Rathmell and Goodnow, 1994) . Inherited mutations in TLR9 or TLR7 delay or suppress appearance of DNA-or RNA-reactive autoantibodies in Fas-deficient mice (Marshak-Rothstein, 2006) , whereas the Yaa mutation that doubles TLR7 accelerates the onset and amount of autoantibody, particularly against RNA-associated antigens such as gp70, from endogenous retroviruses (Merino et al., 1989; Pisitkun et al., 2006) . Taking the above data together, the simplest explanation for the latent period in Fas-deficient mice is that a rate-limiting number of B cell clones are normally present in the peripheral lymphoid repertoire with a predisposing BCR specificity against DNA-or RNAassociated self-antigens. Although Fas overrides T celldriven growth of many self-reactive B cells, these clones preferentially undergo clonal expansion in the absence of Fas because self-DNA and -RNA, when captured by the BCR, have an inherent capacity to trigger TLR7 and TLR9 as if it were of microbial origin, thus bypassing an important growth-limiting mechanism (Marshak-Rothstein, 2006).
The Fas example also reveals that bypass of TLR and Fas checkpoints in B cells is still insufficient for progression to autoimmunity because lymph node enlargement and autoantibodies require the Fas mutation in the T cell lineage as well (Cohen and Eisenberg, 1991) . MHCClass II-reactive CD4 T cells in particular are required for development of anti-DNA autoantibodies in Fasdeficient mice (Jevnikar et al., 1994; Koh et al., 1995) , specifically their CD28 costimulatory receptor (Tada et al., 1999) , their capacity to produce CD40 ligand (Ma et al., 1996) , and their capacity to promote B cell growth and survival in germinal centers (Greenwald et al., 2005; Komori et al., 2006) . Reciprocally, B cells are required to promote the accumulation of activated CD4 T cells and lymph node enlargement in mice lacking Fas (Chan et al., 1999) . They may do this both by direct antigen presentation and indirectly by activating dendritic cells with secreted autoantibody complexes containing self-DNA or self-RNA (Goodnow, 2006) . Multiple checkpoints must therefore be bypassed before autoimmunity arises, and genetic defects in one cell cooperate with defects in another cell to promote a feed-forward reaction that bypasses numerous growth-limit and override mechanisms ( Figures 3B and 3D) .
Inherited defects in other checkpoints also cooperate to shorten the latent phase of autoimmunity in Fas deficient mice. Lymph node enlargement is exaggerated when C57BL/6 Fas-deficient mice are also transgenic for BCL-2-a prosurvival opponent of BIM (Strasser et al., 1995) -or if they lack Bim directly (A. Strasser, P. Bouillet, and P. Hughes, personal communication). Although BCL-2 overexpression or Bim deficiency has little effect on the Fas mechanism of death, it compromises at least four separate override mechanisms: thymic and peripheral deletion of self-reactive T cells and bone marrow and peripheral death of self-reactive B cells (Strasser, 2005) . When overexpression of BCL-2 is restricted to B cells in mice with intact Fas, this is insufficient to cause autoimmunity despite the fact that survival of self-reactive B cells is dramatically increased at several tolerance checkpoints. Overexpression of BCL-2 selectively in T cells is equally insufficient to trigger autoimmune disease. However, when BCL-2 is expressed at sufficiently high levels in B cells and CD4 cells, in C57BL/6 Vav: BCL-2 transgenic strains, the combined defects lead to extensive B cell proliferation in germinal centers by 18 weeks of age and lethal glomerulonephritis in 15%-25% of animals (Egle et al., 2004a) . Of those that live greater than 40 weeks, more than 50% progress to follicular lymphoma. Both the germinal center proliferation and follicular lymphoma are suppressed when CD4 cells are selectively ablated from the animals. Hence it appears that cooperation between T cell and B cell defects is needed before B cells become sufficiently dysregulated that they cause autoimmunity or lymphoma ( Figures 3B  and 3D ).
There are a small number of exceptional circumstances where autoimmunity develops without an apparent latent phase. Deficiency of CTLA4, TGF-β, or FOXP3 results in neonatal autoimmunity characterized by massive activation of T cells Greenwald et al., 2005; Li et al., 2006; Marie et al., 2006) . Similarly, human FOXP3 deficiency results in a neonatal-onset fatal autoimmune and allergic syndrome, immunodysregulation polyendocrinopathy and enteropathy X-linked (IPEX; Bennett et al., 2001 ). The loss of one gene and cell type, FOXP3+ CD4 cells, apparently enables self-reactive T and B cell clones to bypass many other growth-limiting/override checkpoints (Kim et al., 2007) . FOXP3 induces a gene program that inhibits growth of neighboring dendritic cells, T cells, and B cells at multiple checkpoints (Wan and Flavell, 2007; Wu et al., 2006; Zheng et al., 2007) . Unlike AIRE-which appears dedicated to regulating self-reactive cells-the suppressive effects of FOXP3+ cells are also critical for dampening immune responses to environmental antigens. Unbridled inflammation to gut bacteria and food in IPEX syndrome may activate dendritic cells and helper T cells that in turn allow self-reactive clones to bypass normal growth limits. CTLA4 and TGF-β also underpin multiple checkpoints, and both are necessary for the suppressive effects of FOXP3+ CD4+ cells (Greenwald et al., 2005; Li et al., 2006; Marie et al., 2006) .
The evidence above for multiple cooperating events in the pathogenesis of autoimmune disease draws heavily from rare Mendelian disorders where complete defects are inherited. These results can be extrapolated to nonMendelian sporadic autoimmune disease by hypothesizing an accumulation of more subtle inherited defects in the same checkpoints (Liston et al., 2005) . A substantial component of inherited risk of autoimmune disease is due to common variants of the MHC Class II molecules, which markedly change the efficiency of antigen presentation for multiple T cell tolerance checkpoints (Vyse and Todd, 1996) . Unlike mutations in FAS, AIRE, or FOXP3, however, autoimmunity due to susceptible MHC alleles has very low penetrance. Similarly, autoimmune susceptibility in BXSB or NOD mice and KDP rats results from the additive effects of many different genetic loci, each of which has little or no capacity to cause autoimmune disease on its own (Fairhurst et al., 2006; Vyse and Todd, 1996) . Several of these loci have recently been found to compromise the mechanisms described above: the NOD Idd5 locus alters the relative splicing of CTLA4 isoforms (Ueda et al., 2003) ; the BXSB Yaa gene duplicates the gene dose and responsiveness of TLR7 (Pisitkun et al., 2006; Subramanian et al., 2006) ; and the KDP rat Iddm/ kdp1 locus is a nonsense mutation that inactivates CBL-B (Yokoi et al., 2002) .
Mutations in Autoimmunity and Lymphoma
The previous two sections summarize evidence that the potential for relentless growth of self-reactive lymphocytes is normally blocked by a series of checkpoint mechanisms that also prevent lymphoid neoplasia and that autoimmune outgrowths only develop when multiple checkpoints are eventually bypassed. The latent period and sporadic occurrence of autoimmune disease are often put down to an unknown environmental trigger despite clear evidence to the contrary from MRL/lpr, NZB, and NOD mice raised in germ-free and antigenfree conditions. Lymphoma also exhibits a latent period and sporadic occurrence, but in this case the explanation is the need for accumulating somatic mutations in individual clones before they bypass normal growth control checkpoints. Here, I put forward the hypothesis that somatic mutations may represent one of the major stochastic elements in the pathogenesis of autoimmune disease (Figure 3) .
The first reason for considering somatic mutations as a major factor in autoimmunity is because they occur often in lymphocytes. As discussed above, cooperation between inherited mutations in FAS and a specialized type of somatic mutation-V(D)J recombination and hypermutation of antibody genes-is already established in experimental animals. These specialized mechanisms of B cell somatic mutation, together with somatic mutation during isotype switching, are error prone and known to activate oncogenes and inactivate tumor suppressor mechanisms in lymphoma, and they produce a high rate of somatic FAS mutations in normal human germinal centers (Muschen et al., 2000) .
The basal rate of somatic mutation in hematopoietic cells itself creates a large burden. A revealing example comes from children presenting with all of the manifestations of inherited FAS mutations (Canale-Smith syndrome) but who have wild-type FAS genes in their germline (Holzelova et al., 2004) . Autoimmunity in these individuals results from a somatic FAS mutation in a single hematopoietic stem cell that contributes to a small fraction of blood cells. T cell progeny of this mutant clone, and presumably also autoantibody-secreting B cells, selectively expands to account for the severe disease and accumulation of characteristic CD4-CD8-T cells in the blood. Had the somatic mutation occurred in a mature T or B cell it is unlikely to have presented as Canale-Smith syndrome because the mouse models indicate the need for FAS mutations in both T and B lineages to develop the corresponding disorder. However, a FAS mutation in a single B cell or T cell clone combined with other checkpoint defects might present as sporadic autoimmune disease.
Other examples of somatic mutation in hematopoietic cells attest to their frequency. Paroxysmal nocturnal hemoglobinuria results from a PIGA mutation in a hematopoietic stem cell that disables the attachment of the complement inhibitory receptors CD48, CD55, and CD59 to the cell surface via phosphatidylinositol tails. Somatic mutations in this gene can be measured at a frequency of 22 blood cells in every million in normal individuals (Araten et al., 1999) , with a new deleterious mutation arising once in every million cell divisions (Araten et al., 2005) . Consequently, it is not surprising that somatic mutations in adenosine deaminase, IL-7 receptor common gamma chain, or CD3 zeta, occur sufficiently frequently within the first few years of life to give rise to multiple independent revertant T cells in people with inherited mutant alleles despite reversion requiring a specific mutation in a target as small as a single codon (Erickson, 2003; Rieux-Laucat et al., 2006) . It is therefore inevitable that individual lymphocytes will acquire deleterious mutations in many of the tolerance mechanisms described above. Given the growth advantage conferred on self-reactive lymphocytes by such mutations, there seems a high potential for selection and acquisition of several mutations in a single clone ( Figure 3C ).
The second reason for considering somatic mutations as a major stochastic element in the pathogenesis of autoimmunity comes from epidemiological evidence for overlapping pathogenesis of autoimmunity and lymphoma. Large population studies (Bernatsky et al., 2005; Smedby et al., 2006; Zintzaras et al., 2005) show increased incidence of lymphoma in people with pre-existing systemic lupus, rheumatoid arthritis, and Sjogren's syndrome and exclude the drugs used to control autoimmune diseases as a cause (Bernatsky et al., 2006) . The relationship might simply be explained by increased lymphocyte proliferation increasing somatic mutations. However a similarly elevated risk is not seen in other chronic immune responses, such as allergic disease (Soderberg et al., 2006) or inflammatory bowel disease (Smedby et al., 2006) . Moreover, in the case of lymphomas arising in people or mice with inherited FAS mutations, most are B-lymphomas, whereas the predominant lymphoproliferation is of T cells (Straus et al., 2001) . Importantly, somatic FAS mutations in nonHodgkin's lymphoma are predominantly in individuals with a prior history of autoimmune disease (Gronbaek et al., 1998) .
Analysis of malignant lymphomas arising following autoimmune disease indicates evolution from autoreactive cells. In FasL-deficient mice, the B lymphomas express antinuclear BCRs with substitutions typical of DNA-reactive B cells in the autoimmune disease (Zhang et al., 2004) . MALT lymphomas as sequelae of chronic gastric infection with Helicobacter pylori often remit upon antibiotic treatment, apparently because the lymphoma depends upon growth factors from Helicobacter-reactive CD4 cells (Hussell et al., 1996) . One might expect the lymphomas would bear BCRs against the microbe, but instead they frequently bear VH1-69 BCRs binding self-IgG (Bende et al., 2005) . Frequent use of V regions that confer IgG autoreactivity also occurs in MALT lymphomas following Sjogren's syndrome or thyroid autoimmunity, and the MALT1 translocation that activates NF-κB in MALT lymphoma is rarely found in lymphomas with antiself IgG BCRs (Bende et al., 2005) . As IgG-reactive BCRs can capture IgG-chromatin immune complexes to activate NF-κB via TLR9 or TLR7 (Marshak-Rothstein, 2006) , MALT lymphomas appear to dysregulate NF-κB by two alternative pathways: either directly through MALT1 translocation or indirectly through expressing a BCR that captures autologous TLR ligands.
The VH4-34 heavy chain (formerly VH4-21) is frequently used in BCRs borne by malignant clones in cold agglutinin disease, marginal zone lymphomas, and Burkitt's lymphomas (Cappione et al., 2005; Chapman et al., 1996; Silberstein et al., 1991) . This V region confers strong autoreactivity against autologous N-acetyllactosamine determinants on erythrocyte I/i antigen and leukocyte CD45. In normal individuals 5%-10% of the naive follicular pool of B cells bear this V region, but they are inhibited from accumulating in the germinal center, plasma cell, and memory compartments. B cells bearing a CLL-derived VH4-34 BCR with antihuman IgG activity are normally triggered to die by this antigen (Tighe et al., 1995) . These tolerance checkpoints break down in systemic lupus, where VH4-34+ cells become prevalent in germinal centers and secrete anti-leukocyte autoantibodies (Cappione et al., 2005) . In a Burkitt's lymphoma derived from VH4-34+ germinal center cells, BCR binding to self I-I antigen on red cells protected against Fasmediated apoptosis (Schattner et al., 2002) , illustrating how relentless stimulation by self-antigens may be subverted into a growth stimulus in B cells with multiple somatic mutations.
A continuum between autoimmunity and lymphoma has also been shown in celiac disease (Cellier et al., 2000) , where ingested wheat triggers gluten-reactive CD4 T cells and chronic intestinal inflammation. Inflammation remits when wheat flour is avoided, except in a subset of patients where the disease progresses to a wheat-independent gut disease called refractory sprue. Oligoclonal expansions of intraepithelial T lymphocytes accompany this progression, and clonal outgrowths of these T cells follow as enteropathy-associated T cell lymphoma. The clonal T cell outgrowths display TCR-γ rearrangements that may recognize self-antigens.
Rare versus Common Autoimmune Susceptibility Genes As set out in the previous sections, there is a cellular progression between autoimmunity and lymphoid cancer and an overlap in the underlying molecular mechanisms that normally prevent uncontrolled growth of lympho-cytes in both diseases. Views on inherited susceptibility to autoimmunity and lymphoma nevertheless diverge. A prevalent model of autoimmune disease susceptibility focuses upon restricted, common polymorphisms: it results from a few common susceptibility gene variants such as HLA (Todd et al., 1987) and PTPN22 whose high frequency may have been evolutionarily selected in the population because of an advantageous immune response to microbial pathogens. The prevailing view of inherited susceptibility to cancer, by contrast, is one of multiple rare equivalent risk genes (Wright et al., 1999) : it results from many different inherited variants in tumor suppressor genes (like BRCA1), individually representing relatively rare alleles of no particular benefit that are unique to particular families or populations but whose cumulative effect is substantial (Fearnhead et al., 2004) . Given the large number of tolerance checkpoints and genes preventing growth of self-reactive lymphocytes and their overlap with tumor suppressor mechanisms, it is reasonable to expect that inherited susceptibility to autoimmunity will parallel that of cancer and involve many equivalent rare alleles.
The germline mutation rate, multiplied over a large number of tolerance genes, makes a multiequivalent mode of inherited autoimmune susceptibility inevitable when compounded by the somatic mutation rate discussed earlier. By various measures the germline rate is one new deleterious mutation per average protein-coding gene per 100,000 generations (Haag-Liautard et al., 2007; Pritchard, 2001) . As there are ?25,000 protein-coding genes, this corresponds to a new deleterious mutation arising in every fourth child. In a large, outbreeding human population of many million, this rate multiplied over several hundred critical tolerance genes and several hundred recent generations translates into a massive influx of new deleterious alleles into our current population. Aside from genes on the X chromosome and very specific mutations with dominant-negative effects like some FAS alleles, the majority of these mutations will have low penetrance in heterozygous state, and their frequency will mostly be determined by genetic drift and founder effects in particular families and populations (Pritchard, 2001) . It is therefore likely that each of us carries multiple deleterious rare mutations in critical tolerance genes in heterozygous state. However, given the somatic mutation rate of 10 −6 per gene per cell division (Araten et al., 2005) and the fact that billions of lymphocytes are produced before adulthood, it is inevitable that for each gene where we inherit a heterozygous deleterious allele, the remaining functional copy will have been lost to somatic mutation in many independent lymphocyte clones ( Figure 3 ). As we have seen above, self-reactive clones with complete loss of genes such as FAS, BIM, CBLB, or CTLA4 have a marked growth advantage because they bypass key growth limit or override checkpoints. As autoimmunity nevertheless has a sporadic onset even when all cells carry germline mutations that bypass tolerance mechanisms, it will occur even more sporadically and be indiscernible as a distinct inherited disorder when a heterozygous defect is inherited and the second hit occurs stochastically in individual lymphocytes or hematopoietic progenitors. Like cancer, many equivalent rare inherited variants may eventually manifest in common autoimmune disease endpoints that appear indistinguishable by our current diagnostic tools.
Practical Implications
There are several practical implications of this multistep view of autoimmune pathogenesis. First, sporadic autoimmune diseases that appear equivalent may be distinguished by testing known tolerance genes for heterozygous deleterious mutations in the germline. Inheritance of a heterozygous defect may predict the pathway by which autoimmune clones have bypassed normal checkpoints somatically, whereas detecting somatic second hits in self-reactive clones would be more difficult. Identification of germline or somatic mutations would provide a way to stratify the likelihood of response to pathway-specific therapeutics as is the case for treatment of chronic myeloid leukemia with Gleevec. Second, the multistep hypothesis for autoimmunity suggests cancerrelated strategies aimed at eliminating the rogue clones of autoimmune cells. If the autoimmune driver clones are partially dysregulated by inherited and somatic mutations, then, like cancer cells, they may be hypersensitive to particular drugs compared to their normal counterparts and thus selectively eliminated. For example, the efficacy of cancer therapeutics such as Rituximab against some autoimmune diseases and their capacity to suppress autoimmunity to a greater degree than immunity to infection may stem from somatic mutations that sensitize the autoimmune clones.
Note
Since submitting this manuscript, my colleague Dr. Stephen Daley has drawn my attention to F.M. Burnet's extraordinary 1972 book (Burnet, 1972) . This monograph assembled the limited information about lymphocytes at that time to arrive at the same hypothesis developed here-that the stochastic onset of autoimmunity reflects "a conditioned malignancy" caused by emergence of "forbidden clones" through a combination of germline and somatic mutations that disrupt the normal mechanisms for eliminating or inactivating self-reactive lymphocytes.
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